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Abstract Psoriatic arthritis (PsA) is a chronic condition char-
acterized by a diverse set of symptoms, from swollen joints to
nail disease to skin disease. A variety of treatment options are
available, including tumor necrosis factor inhibitors (TNFis).
Little is known about treatment persistence in patients with
PsAwho initiate TNFi therapy, with and without prior biolog-
ic use. This study assessed persistence in these subgroups of
patients with PsA and identified factors associated with per-
sistence. This retrospective study utilized data from the
Corrona registry of patients with PsA—with or without prior
biologic experience—who initiated TNFi therapy between
October 1, 2002, and March 21, 2013. Kaplan-Meier curves
estimated median time to nonpersistence (discontinuation or
switch to another biologic). Cox proportional hazards models
identified factors associated with TNFi nonpersistence. A total
of 1241 TNFi initiations were identified: 549 by biologic-
naïve and 692 by biologic-experienced patients. Through
4 years of follow-up, more biologic-naïve than biologic-
experienced patients remained persistent. Biologic-naïve pa-
tients had a greater mean time to nonpersistence compared
with biologic-experienced patients: 32 vs 23 months
(p = 0.0002). Moderate and high disease activities based on
clinical disease activity index and disease duration were asso-
ciated with persistence in both biologic-naïve and biologic-
experienced patients. Additionally, in the biologic-
experienced patients, the number of prior medications and
skin disease were associated with persistence. The majority
of patients with PsA in this study were persistent with their
TNFi therapy; biologic-naïve patients had greater persistence
compared with biologic-experienced patients. Predictors of
persistence differed slightly between biologic-naïve and
biologic-experienced patients.
Keywords Biologics . Disease severity . Persistence .
Psoriatic arthritis . Tumor necrosis factor inhibitors
Introduction
Psoriatic arthritis (PsA) is an increasingly common chronic
systemic inflammatory disease that affects both the skin and
the musculoskeletal system [1–3]. PsA can be characterized
by pain and swelling of the joints, dactylitis, enthesitis, nail
disease, and skin disease and increases the risk of cardiovas-
cular disease and metabolic syndrome [4, 5]. The use of ef-
fective treatment improves patients’ functionality and quality
of life by reducing skin and joint involvement and preventing
permanent joint damage [6]. Treatment options for PsA in-
clude nonsteroidal antiinflammatory drugs (NSAIDs),
nonbiologic disease-modifying antirheumatic drugs
(nbDMARDs), biologic agents (including tumor necrosis fac-
tor inhibitors [TNFis]), and small molecules (including
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phosphodiesterase and Janus kinase inhibitors) [7]. From the
rheumatoid arthritis (RA) literature, it has been demonstrated
that use of these therapies is associated with a high rate of
nonpersistence, attributed to dosing, route of administration,
efficacy, and side effects.
Treatment persistence and prior biologic use are well doc-
umented in patients with RA and psoriasis; however, less is
known about persistence in patients with PsA [8–14]. PsA is
manifested in a diverse range of symptoms, and symptom
severity varies over time, which complicates treatment and
may influence treatment persistence [15, 16]. Factors associ-
ated with persistence differ based on prior biologic experi-
ence. The current study was undertaken to address this knowl-
edge gap by describing persistence with TNFi in patients with
PsA and to identify predictors of persistence, including the
role of prior biologic use. This study provides a better under-
standing of the factors that influence discontinuation and




The present study was a retrospective analysis of observation-
al data collected on patients with PsAwho participated in the
Corrona registry and who initiated TNFi therapy.
Data source
Corrona is a large, US-based, independent, prospective, ob-
servational, disease-based registry with information on rheu-
matology patients, including those with PsA, since 2001.
Patients are enrolled in the registry by participating rheuma-
tologists, and questionnaires are completed by both patients
and physicians as part of routine clinical care during clinical
encounters. Data collection is not mandated at regular inter-
vals; however, rheumatologists are encouraged to complete
the questionnaires at least every 6 months. This registry en-
compasses over 160 sites across 40 states, including over 600
rheumatologists and 6000 patients with PsA (about 13% of the
registry). This study has been performed in accordance with
the ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments.
Study population
Patients from the Corrona registry were included in this study
if they had a physician-recorded diagnosis of PsA; initiated
therapy (i.e., the index date) with a TNFi (i.e., adalimumab,
etanercept, golimumab, or infliximab) between October 1,
2002, and March 21, 2013; and were at least 18 years of age
at the index date. Included patients also had ≥1 follow-up visit
captured in the registry after initiation of TNFi therapy.
Patients were excluded from this study if they had a diagnosis
other than PsA for which any of the qualifying TNFis might
be used (e.g., ankylosing spondylitis, Crohn’s disease, plaque
psoriasis, RA, and ulcerative colitis).
Patients in this study were dichotomized as being persistent
or nonpersistent. Patients were observed from the index date
until the earliest instance of one of the following: last follow-
up visit or nonpersistence (defined as discontinuation of TNFi
therapy, switch to another biologic or small-molecule therapy,
or a ≥1-year gap between follow-up visits).
Patients were further stratified by biologic experience.
Biologic-naïve patients had no record of prior biologic use at
TNFi initiation. Biologic-experienced patients had any record
of prior biologic use at TNFi initiation.
Statistical analyses
Demographic and clinical characteristics were described at the
index date. Kaplan-Meier curves were used to estimate medi-
an time to nonpersistence (i.e., discontinuation or switch to
another biologic). Follow-up extended through the last visit
for patients who were still on therapy at their last follow-up
visit. Follow-up time was censored at the start of a gap in data
if a patient had a gap ≥1 year between two visits before
experiencing a discontinuation/switch event or last follow-up
visit. A log-rank test was used to assess differences in persis-
tence between patients who were biologic-naïve and biologic-
experienced at the index date. Multivariate models were cre-
ated to identify factors associated with TNFi nonpersistence
with separate models for biologic-naïve and biologic-
experienced patients. Univariate Cox proportional hazards
models evaluated potential predictors: history of biologic
use, patient demographics, history of comorbid conditions,
and treatment history as of the index date; with the exception
of gender, race, education, and treatment history as of the
index date, all factors could vary over time. All factors that
demonstrated a significant association with nonpersistence in
the univariate models (p < 0.20) were then evaluated in mul-
tivariate Cox proportional hazards models, with the hazard
ratios (HRs) from these two final models quantifying the ef-
fect of each factor as a predictor of nonpersistence for the
biologic-naïve and biologic-experienced subpopulations.
Results
After applying the patient eligibility criteria, a total of 1241
TNFi initiations were identified for this study. These patients
had a mean (standard deviation [SD]) age of 51 (12) years,
55% were female, 93% were white, and the study population
had a mean (SD) PsA duration of 8 (9) years (Table 1). At the
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index date, mean (SD) clinical disease activity index (CDAI)
was 14.6 (12), and the largest proportion of patients (44%) had
CDAI ≤10 (i.e., low disease activity [LDA]; Table 2). The
majority of patients had used a biologic (56%) or nonbiologic
disease-modifying antirheumatic drug (nbDMARD) (86%)
prior to initiating the index TNFi; 543 (44%) received mono-
therapy and 698 (56%) received combination therapy
(Table 3). Tables 1, 2, and 3 also provide patient characteris-
tics for biologic-naïve and biologic-experienced patients.
Time to TNFi nonpersistence
Overall, 46% of patients discontinued TNFi therapy during
this study, with the number of persistent patients dropping
from 83.2% at 6 months to 36.1% at 48 months. The
follow-up time observed in this study was 1810.67 per-
son-years. The median (95% confidence interval [CI]) time
to discontinuation among all patients was 27 (25,
31) months. Among the 1241 TNFi initiations, there were
572 instances of nonpersistence, of which 309 instances
were of switching.
Biologic-naïve patients were consistently more persis-
tent than their biologic-experienced counterparts at all time
points assessed over 4 years of follow-up (Fig. 1). At
6 months, 87% of biologic-naïve and 80% of biologic-
experienced patients were persistent; at 48 months, 42
and 31%, respectively, were persistent. The median (95%
CI) time to discontinuation among biologic-experienced
and biologic-naïve patients was significantly different: 23
(18, 29) vs 32 (27, 37) months (p = 0.0002 from log-rank
test; Fig. 2).
Predictors of TNFi nonpersistence
Multivariate Cox proportional hazard models were completed
separately for biologic-naïve and biologic-experienced
Table 2 Patient disease severity
at index date Characteristic






CDAI, mean (SD) 14.6 (12.0) 14.5 (11.4) 14.6 (12.5)
Low (≤10), n (%) 533 (44.4) 226 (43.1) 307 (45.3)
Moderate (>10 and ≤22), n (%) 398 (33.1) 183 (34.9) 215 (31.8)
High (>22), n (%) 270 (22.5) 115 (21.9) 155 (22.9)
28 tender joint count, mean (SD) 4.7 (6.4) 4.3 (5.6) 5.0 (6.9)
28 swollen joint count, mean (SD) 3.3 (4.8) 3.8 (5.1) 2.9 (4.4)
HAQ, mean (SD) 0.65 (0.65) 0.59 (0.61) 0.69 (0.67)
PGA, mean (SD) 27.0 (20.8) 27.8 (20.7) 26.5 (20.9)
PtGA, mean (SD) 38.0 (26.1) 35.9 (24.9) 39.7 (26.9)
CDAI clinical disease activity index, HAQ health assessment questionnaire, PGA physician global assessment,
PtGA patient global assessment, SD standard deviation, TNFi tumor necrosis factor inhibitor
a Sample sizes (if not 1241): CDAI = 1201; 28 tender joint count = 1234; 28 swollen joint count = 1235;
HAQ = 436; PGA = 1239; PtGA = 1207
Table 1 Patient demographic
and clinical characteristics at
index date






Age (years), mean (SD) 50.7 (12.1) 50.6 (12.7) 50.8 (11.6)
Sex (female), n (%) 675 (54.7) 274 (50.2) 401 (58.2)
Race (white), n (%) 1153 (92.9) 512 (93.3) 641 (92.6)
PsA duration (years), mean (SD) 8.3 (8.5) 6.7 (8.3) 9.5 (8.4)
History of CV disease,b n (%) 67 (5.4) 29 (5.3) 38 (5.5)
History of cancer (except NMSC), n (%) 53 (4.3) 21 (3.8) 32 (4.6)
History of diabetes, n (%) 131 (10.6) 53 (9.7) 78 (11.3)
CV cardiovascular, CVD cardiovascular disease, NMSC nonmelanoma skin cancer, PsA psoriatic arthritis, SD
standard deviation, TNFi tumor necrosis factor inhibitor
a Sample sizes (if not 1241): age = 1233; female = 1235; duration of PsA = 1236
bHistory of any CVD event including acute coronary syndrome, coronary artery disease, congestive heart failure,
myocardial infarction, or peripheral arterial disease
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patients; models were adjusted for female gender, race, age,
body mass index, smoking status, comorbidity, and concomi-
tant prednisone use. In both biologic-naïve and biologic-
experienced patients, activity based on the CDAI was associ-
ated with an increased risk of nonpersistence, although the
magnitude of the association was greater in biologic-naïve pa-
tients: moderate CDAI (vs LDA) HR (95% CI) = 2.5 (1.5, 4.3)
and 1.6 (1.1, 2.3) for biologic-naïve and biologic-experienced
patients, respectively, and high CDAI (vs LDA) HR (95%
CI) = 2.2 (1.1, 4.1) and 1.6 (1.0, 2.5) for biologic-naïve and
biologic-experienced patients, respectively (Table 4). Shorter
disease duration was also associated with better persistence in
both biologic-naïve and biologic-experienced patients. In
patients who were biologic-experienced, the risk of discontin-
uation was higher among patients with prior nbDMARD treat-
ment compared with patients with no prior nbDMARD treat-
ment; the risk of discontinuation was also greater among pa-
tients with greater skin involvement (i.e., a high [>20] vs low
[≤20] score on the physician global skin assessment).
Discussion
Based on results from a nationwide cohort of patients with PsA,
slightly more than half (52%) of the patients included in this
study were persistent with their TNFi therapy at 24 months
Table 3 Patient PsA treatment history at index date






Prior biologics, n (%)
0 549 (44.2) 549 (100.0) 0 (0.0)
1 454 (36.6) 0 (0.0) 454 (65.6)
≥2 238 (19.2) 0 (0.0) 238 (34.4)
Prior nbDMARDs, n (%)
MTX 992 (79.9) 427 (77.8) 565 (81.6)
Other nbDMARD 72 (5.8) 31 (5.6) 41 (5.9)
Number of prior nbDMARDs,b mean (SD) 0.7 (0.9) 0.5 (0.8) 0.9 (1.0)
Concomitant medication, n (%)
MTX 560 (45.1) 279 (50.8) 281 (40.6)
MTX + other nbDMARD 45 (3.6) 23 (4.2) 22 (3.2)
Other nbDMARD 93 (7.5) 27 (4.9) 66 (9.5)
Prednisone 129 (10.4) 50 (9.1) 79 (11.4)
MTX methotrexate, nbDMARD nonbiologic disease-modifying antirheumatic drug, PsA psoriatic arthritis, SD standard deviation, TNFi tumor necrosis
factor inhibitor
a If a patient indicates initiation of drug Bprior to visit,^ then the disease characteristics at prior visit will be used, and history and concomitant drug use at
index visit will be used
b Excludes current use
Fig. 1 Percentage of biologic-
naïve and biologic-experienced
patients with PsAwho were
persistent over time. The
percentage (95% CI) of patients
with PsAwhowere persistent at 6,
12, 24, 36, and 48 months in
biologic-naïve (light gray bars)
and biologic-experienced (dark
gray bars) patients.CI confidence
interval, PsA psoriatic arthritis,
TNFi tumor necrosis factor
inhibitor
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after initiation. Biologic-naïve patients had greater persistence
compared with biologic-experienced patients. Increased dis-
ease activity was associated with a greater risk of
nonpersistence in both groups. The magnitude of this associa-
tion was greater in biologic-naïve patients compared with
biologic-experienced patients.
Table 4 Covariates associated
with tumor necrosis factor
inhibitor discontinuation





Gender (female vs male) 1.00 (0.65, 1.53) 1.22 (0.91, 1.63)
Agea 1.00 (0.99, 1.02) 1.00 (0.99, 1.01)
Race (white vs nonwhite) 0.64 (0.29, 1.41) 1.13 (0.63, 2.02)
BMIb 1.02 (0.99, 1.05) 0.98 (0.96, 1.01)
Smoking status (previous/current vs never) 0.99 (0.65, 1.51) 1.27 (0.96, 1.69)
Work status (full/part-time vs all others) 0.84 (0.53, 1.33) 1.11 (0.81, 1.52)
CCIb
1 vs 0 1.32 (0.81, 2.15) 0.84 (0.60, 1.19)
≥2 vs 0 2.50 (0.99, 6.29) 0.85 (0.47, 1.57)
PsA characteristicsc
Disease duration 0.96 (0.92, 0.99) 0.99 (0.97, 1.00)
Number of prior nbDMARDsd 1.18 (0.78, 1.79) 1.40 (1.04, 1.89)
Current prednisone use 1.42 (0.72, 2.83) 1.48 (0.99, 2.23)
Patient-reported pain 1.00 (1.00, 1.01) 1.00 (0.99, 1.01)
CDAI
Moderate disease activity (vs LDA)e 2.50 (1.47, 4.27) 1.62 (1.13, 2.32)
High disease activity (vs LDA)f 2.15 (1.11, 4.13) 1.60 (1.01, 2.53)
Physician global skin assessment 1.18 (0.74, 1.87) 1.38 (1.01, 1.87)
AIDS acquired immunodeficiency syndrome, BMI body mass index, CCI Charlson Comorbidity Index, CDAI
clinical disease activity index, CI confidence interval, HR hazard ratio, LDA low disease activity, nbDMARD
nonbiologic disease-modifying antirheumatic drug, PsA psoriatic arthritis
a Continuous
b Excludes PsA. The Corrona registry does not capture the following comorbid conditions that are included in the
CCI: dementia, kidney disease, hemiplegia, and AIDS
cAssessed at the index date
d Excludes current use
eModerate disease activity: 10 < CDAI ≤ 22; LDA: CDAI ≤10
f High disease activity: CDAI >22
Fig. 2 Time to TNFi
discontinuation in biologic-naïve
and biologic-experienced
patients. Time to discontinuation
of TNFi in biologic-naïve (light
gray curve) and biologic-
experienced (dark gray curve)
patients. Median (95%CI) time to
discontinuation is indicated for
each subgroup. CI confidence
interval, TNFi tumor necrosis
factor inhibitor
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Persistence is often associated with treatment efficacy
[8–14]. The current study provides insight into the factors that
influence persistence with a TNFi and how persistence differs
based on prior exposure to biologics. Specifically, in patients
who were biologic-naïve, disease duration and disease activity
were associated with persistence. In addition to these factors,
in patients who were biologic-experienced, prior medications
and physician global skin assessment were also associated
with persistence.
Most of the existing data on persistence and treatment out-
comes describe patients with RA; there are fewer studies de-
scribing patients with PsA. Previous data indicate that patients
with RAwho fail their first biologic therapy experience worse
efficacy on their second biologic [17–20]. Patients who are
biologic-naïve experience better efficacy when they start a
new biologic compared with patients who are biologic-experi-
enced. The association between biologic experience and per-
sistence is fairly well established in RA populations [5, 21, 22];
our study adds to the limited evidence suggesting that the pat-
tern is similar in patients with PsA [23, 24]. Our overall rate of
discontinuation was 46% including stopping, switching, or
having a ≥1-year gap in treatment. In comparison, a study
based on the DANBIO registry found that 39% of patients
switched treatment and 17% of patients stopped treatment
[24]. Of note, that studywas focused on biologic-naïve patients
only. Our findings are also consistent with another study that
reported that, among patients whowere biologic-naïve at TNFi
initiation, there was no difference in persistence with TNFi
between patients who initiated combination therapy (with
methotrexate) and those who initiated monotherapy [25].
Physicians who are treating biologic-naïve patients may be
more willing to switch them to a new drug when their disease
activity increases because they havemore remaining therapeu-
tic options available to try. Such a scenario would be consis-
tent with our findings. Similarly, physicians may be less will-
ing to quickly switch biologic-experienced patients when their
disease activity increases because those patients have fewer
remaining therapeutic options available to try [26]. Both of
these scenarios suggest careful consideration in choosing the
initial biologic to increase the likelihood of a favorable out-
come with the first drug used. Even with such careful consid-
eration, some patients may experience increases in disease
activity and may need to switch to a different TNFi. The
findings from this study overall suggest the need for careful
and continued monitoring to ensure that patients remain per-
sistent in order to enhance their opportunity to obtain the
greatest therapeutic benefit from any TNFi that they may be
using. Monitoring may also help physicians intervene and
switch patients to a different medication when necessary.
An important strength of this study is its use of data from a
national cohort of patients receiving care in both academic and
private practice settings. As such, this study provides insights
into TNFi persistence in the real-world, routine care setting.
Although one limitation associated with all real-world obser-
vational studies is that the patients enrolled in the registries
may not be generalizable to patients in general practice, a
recent study confirmed that Medicare patients represented in
the Corrona registry are similar to the national Medicare pop-
ulation with regard to demographic characteristics, suggesting
that data collected from patients in the Corrona registry may
be generalizable to patients with RA in the USA [27]. As with
most observational studies, there is the potential for selection
bias in our study, especially given that the patients in our study
entered the Corrona registry at the discretion of their treating
rheumatologist. The PsA treatment landscape is evolving,
with the availability of new agents possibly changing patterns
of persistence. This issue was at least partially addressed by
our decision to evaluate treatment-related covariates in a time-
varying fashion for the models assessing predictors of persis-
tence. Finally, we did not have access to data on reasons for
TNFi discontinuation; consequently, the observed treatment
nonpersistence could reflect either treatment success (i.e.,
achievement of LDA or remission) or failure (i.e., increased
disease activity or worsening of symptoms).
Conclusion
The majority of patients with PsA assessed in this study were
persistent with their TNFi therapy. When patients were strat-
ified based on their previous biologic exposure, biologic-
naïve patients had greater persistence compared with their
biologic-experienced counterparts. While predictors of persis-
tence differed slightly between biologic-naïve and biologic-
experienced patients, disease activity was significant in both
subgroups, although the magnitude of the association was a
greater predictor for biologic-naïve compared with biologic-
experienced patients. Understanding the factors associated
with persistence in patients with PsA with different biologic
experience may be important for making treatment decisions.
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